Hemispherx (HEB) Higher Ahead of Purported Update On Ampligen

After raminig into the close yesterday, Hemispherx Biopharma, Inc. (AMEX: HEB) is higher again this morning. According to TheStreet.com's biotech reporter Adam Feuerstein, stock promoting website BioMedReports will release a special report on Hemispherx "during market hours" today about the long-delayed Ampligen drug.

BioMedReports said "Dr. William A. Carter, CEO of Hemispherx BioPharma, Inc. is expected to share some important news about the company's pending FDA decision and some new information about the company's Alferon LDO (Low Dose Oral) application."

Feuerstein askes "If Carter has important, material news on the regulatory status of Ampligen, why is he allegedly front-running the announcement to a stock promoter?" Good question.

Shares of HEB rose 13% yesterday and is up another 10% this AM.

Real-Time Market Moving News Two-Weeks FREE http://www.streetinsider.com/premium_content.php

You May Also Be Interested In

• Equifax (EFX) shares tumble on weak Q1 revenue, guidance miss
• Eli Lilly (LLY) sleep apnea study data seen as a win, stock gains
• Autodesk says it will not submit 10-K report within 15-day grace period, shares down